XTL Biopharmaceuticals
XTLB
4 hedge funds and large institutions have $208K invested in XTL Biopharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 1 closing their positions.
7% more capital invested
Capital invested by funds: $194K → $208K (+$14K)
0.13% less ownership
Funds ownership: 1.94% → 1.81% (-0.13%)
20% less funds holding
Funds holding: 5 → 4 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$10.5K |
| 2 |
Morgan Stanley
New York
|
+$6.17K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.03K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$33K |
XTLB Hedge Fund Activity: Q3 2018 in Review
4 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q3 2018, worth a combined $208K — up 7.2% from $194K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of XTLB and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 3 added.
The largest buyer was UBS Group, adding an estimated $10.5K. The largest seller was Citadel Advisors, exiting entirely with an estimated $33K sold.
- 4 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q3 2018, down from 5 in Q2 2018.
- Funds reported $208K of XTL Biopharmaceuticals stock for Q3 2018, up 7.2% quarter-over-quarter.
- 0 funds opened new XTL Biopharmaceuticals positions in Q3 2018 and 1 closed out, a net change of -1 holder.
- The largest XTL Biopharmaceuticals buyer in Q3 2018 was UBS Group, an estimated $10.5K added.
- The largest XTL Biopharmaceuticals seller in Q3 2018 was Citadel Advisors, an estimated $33K sold.
Based on aggregated 13F filings for Q3 2018.